Observational studyWorld journal of urology2026
Clinical patterns and pathogenesis of bladder leiomyoma: a multicenter observational study.
Observational study in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the clinical and tumor characteristics of bladder leiomyoma (BL) and to explore potential etiological factors and prognostic factors to guide management strategies.
methodsPatients with histologically confirmed BL treated at 14 hospitals between 1995 and 2025 were included. Associations between tumor characteristics, symptoms, management, and outcomes were evaluated using appropriate statistical tests and logistic regression. A p-value < 0.05 was considered significant.
resultsAmong 74 patients (55.4% female, median age 60 years [IQR, 42.25-70.00]), 48.6% were asymptomatic at diagnosis, and 66.2% presented with at least one metabolic syndrome criterion. Tumors had a median size of 21.0 mm [IQR 13.50-35.00] and were most frequently endovesical (48.6%), followed by intramural (35.1%) and extravesical (16.2%) patterns; tumor size and location were not associated with preoperative symptoms but significantly influenced surgical management (p = 0.002). Transurethral bladder resection was the most common treatment (62.2%), followed by partial cystectomy (23.0%) and bladder excision (9.5%), with 68.8% of them performed laparoscopically. Early postoperative complications occurred in 8.1% of patients. Over a median follow-up of 14.3 months [IQR 2.3-48.0], recurrence occurred in 5.4% and persistent or worsening symptoms in 17.6% of patients. Initial LUTS were predictive of both recurrence and persistent postoperative symptoms (OR = 2.02 [1.20-4.61] and 2.38 [1.53-4.55], respectively).
conclusionThis study represents the largest cohort of BL to date. The high proportion of asymptomatic cases suggests that its true incidence is underestimated. While recurrence was uncommon, persistent LUTS remained a concern among initially symptomatic patients, supporting a personalized, conservative therapeutic approach whenever feasible. Further studies are needed to clarify the biological mechanisms underlying BL and to optimize its management.
Indexed as
Identifiers
42517939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.